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Abstract: Emerging evidence shows that long noncoding RNAs (lncRNAs) participate in various cellular processes, and that
plasmacytoma variant translocation 1 (PVT1), a newly described oncogene that interacts with various molecules such as p15, p16,
NOP2, and c-Myc, is a major contributing factor in tumor development. However, the role of this oncogene remains unknown in the
pathogenesis of acute lymphoblastic leukemia (ALL), the most prevalent form of childhood leukemia. In this study, we first measure the
expression level of PVT1 in a Jurkat cell line, then small interfering (siRNA) PVT1 is applied to demonstrate the impact of PVT1 knockdown in apoptosis, proliferation, the cell cycle, and its downstream targets. Our findings show that lncRNA was significantly higher in
the ALL cell line than normal lymphocytes and that PVT1 knock-down increased the rate of apoptosis, caused G0/G1 arrest in the cell
cycle, reduced the proliferation rate, and, above all, reduced the stability of c-Myc protein. All findings were confirmed at the molecular
level. Our results may indicate the role of PVT1 knock-down in the suppression of ALL development and might provide an option for
targeted therapy for leukemic conditions.
Key words: Long noncoding RNA, PVT1, acute lymphoblastic leukemia, c-Myc, siRNA

1. Introduction
Acute lymphoblastic leukemia (ALL), which occurs in
both children and adults, is characterized by uncontrolled
proliferation of T or B lymphoblasts. The incidence rate of
this form of leukemia is much higher in children between
2 and 5 years of age and it is considered to be the most
common cause of cancer deaths in children in the United
States (Pui et al., 2008). Wide genomic alterations such as
somatic mutation in PAX5, deletion of E2A and IKZF1, and
chromosomal rearrangements are considered hallmarks of
ALL that perturb the diverse signaling pathways involved
in vital cellular processes (Mullighan et al., 2007; Gu et al.,
2016). Various oncogenes, such as TAL1, LMO2, HOX
A, and c-Myc, participate in the development of ALL.
However, c-Myc, which is downstream of the Notch-1
signaling pathway, plays an important role in promoting
cell growth and in the proliferation of malignant cells
(Kamdje and Krampera, 2011; Gu et al., 2016). Different
studies showed that while this axis is augmented in about
50% of ALL cases, applying different c-Myc inhibitors

increases cell death and is an effective therapeutic option
for ALL patients (Delgado and León, 2010; Roderick et al.,
2014).
Long noncoding RNAs (lncRNAs) are noncoding
transcripts larger than 200 nucleotides that have a role
in a variety of biological processes such as the cell cycle,
apoptosis, epigenetic regulation, and imprinting (Kung
et al., 2013; Garzon et al., 2014). Mounting evidence
demonstrates the participation of various lncRNAs,
including HOTAIR, H19, GAS5, and RUNXOR, in the
pathogenesis of several malignancies such as breast cancer
and leukemia (Wei and Wang, 2015). Plasmacytoma variant
translocation 1 (PVT1), located in the chromosomal
region of 8q24 downstream of MYC, has various roles
in both normal and malignant conditions (Zeng et al.,
2015). This cancer-related region has drawn the attention
of researchers because of its role in DNA rearrangement,
direct interaction with c-Myc, and production of about
twenty lncRNAs and six microRNAs (Colombo et al., 2015).
It has been shown that the expression of lncRNA PVT1
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is associated with enhanced proliferation and invasion
of osteosarcoma, small cell lung cancer, and melanoma.
Treatment with siRNA-PVT1 results in cell cycle arrest,
apoptosis, and the suppression of proliferation (Huang
et al., 2016; Zhou et al., 2016; Wang et al., 2018). It has
been elucidated that serum levels of PVT1 are increased in
gastric cancer, small cell lung cancer, and cervical cancer,
all of which are accompanied by low overall survival rates.
Therefore, lncRNA PVT1 can be considered a diagnostic
marker and a suitable therapeutic target (Kong et al., 2015;
Cui et al., 2016; Yang et al., 2016).
Due to the importance of c-Myc in ALL pathogenesis
and considering the fact that lncRNA PVT1 potentiates
and stabilizes this oncogene, we resolved to demonstrate
for the first time the role of PVT1 knock-down in the
suppression of ALL development.
2. Materials and methods
2.1. Cell culture
Jurkat cells were cultivated in a T25 flask in Roswell Park
Memorial Institute (RPMI) 1640 medium with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin and
maintained in a humidified incubator containing 5% CO2
at 37 °C.
2.2. RNA interference
To determine the effect of PVT1 knock-down, we
purchased two siRNAs against lncRNA PVT1 that
interact with two different parts of the PVT1 mRNA
sequence (Hs_PVT1_5 FlexiTube siRNA and Hs_PVT1_6
FlexiTube siRNA) (QIAGEN, Germany). AllStars negative
control siRNA (QIAGEN) was used as the negative
control. Twenty-four hours prior to the treatment, 105 cells
were seeded in each well of a 24-well plate. Transfection
of the siRNAs was performed by applying Lipofectamine
3000 according to the manufacturer’s protocol (Invitrogen,
USA). All experiments were performed 48 h after siRNA
transfection.
2.3. Real-time polymerase chain reaction
Total RNA from the transfected cells was extracted using
QIAzol reagent (QIAGEN). After the qualification using a
NanoDrop spectrophotometer (Thermo Fisher Scientific,
USA), the extracted RNA was reverse-transcribed into
cDNA using a cDNA synthesis kit (Takara, USA). Realtime polymerase chain reaction (RT-PCR) was performed
by applying SYBR Green Master Mix (Takara). The results
were normalized with beta actin (ACTB) as an internal
control and the relative expression fold changes of the
mRNAs and lncRNA were calculated using the 2–ΔΔCt
method. The following primers were designed: PVT1: 5¢
GTGCTCTGTGTTCACCTGGTTCATC 3¢ (forward) and
5¢ GCCCGTTATTCTGTCCTTCTCATG 3¢ (reverse).
c-Myc: 5¢ AGCGACTCTGAGGAGGAAC 3¢ (forward)
and 5¢ CTGCGTAGTTGTGCTGATG 3¢ (reverse). Bcl2:
5¢ CAACATCACAGAGGAAGTAG 3¢ (forward) and 5¢
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GGAACACTTGATTCTGGTG3¢ (reverse). Caspase-3:
5¢ ATTGATGCGTGATGTTTCTAAAG 3¢ (forward)
and 5¢ CAATGCCACAGTCCAGTTC 3¢ (reverse).
p15: 5¢ CTGGACCTGGTGGCT ACG 3¢ (forward) and
5¢ ACATTGGAGTGAACGCATCG3¢ (reverse). p16:
5¢ AAGGTC CCTCAGACATCC3¢ (forward) and 5¢
TCGGTGACTGATGATCTAAG3¢ (reverse).
2.4. c-Myc protein expression assay
Intracellular c-Myc protein expression was detected in
the treated and control groups by flow cytometry using
a primary antibody against human c-Myc protein and
fluorescein isothiocyanate (FITC)-conjugated secondary
antibody (Dako, Denmark). Before the antibody reaction,
cells were treated with reagents from a permeabilization kit
(Dako) according to the manufacturer’s instructions. The
mean fluorescence intensity (MFI) of the antibody-reacted
cells as a protein expression level and the percentage of
reacted cells were evaluated in both the control and treated
groups.
2.5. Western blotting
The total proteins were extracted from each study group
using lysis buffer, and after quantification of the protein
concentration using a bicinchoninic acid (BCA) protein
assay kit (Thermo Scientific, USA), equivalent amounts
of protein were subjected to 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis for 90 min.
Subsequently, the separated proteins were transferred to
a Millipore 0.45 µm polyvinylidene difluoride (PVDF)
membrane and blocked in washing buffer containing
5% nonfat dry milk for 1 h at room temperature. The
membranes were then confronted with anti-β-actin and
anti-c-Myc (all from Abcam, USA) at 4 °C for 24 h and,
following that, HRP-conjugated antimouse antibody at
25 °C for 2 h. Finally, the protein bands were visualized
with Bio-Rad (USA) Trans-Blot and band intensities
were quantified using TotalLAB software version 1.10
(TotalLAB, UK).
2.6. Apoptosis assay
An apoptosis assay was performed to analyze the role of
PVT1 knock-down in the enhancement of apoptosis in
leukemic cells. Briefly, the cells were washed using PBS
and resuspended in the binding buffer. Then 5 µL of FITCconjugated annexin V and 5 µL of propidium iodide were
added to the samples and incubated for 10 min at room
temperature. The experiment was carried out using flow
cytometry.
2.7. Carboxyfluorescein diacetate N-succinimidyl ester
cell division assay
To assess the role of PVT1 in the proliferation of Jurkat
cells, a carboxyfluorescein diacetate N-succinimidyl ester
(CFSE) cell division assay was performed after siRNA
treatment according to a related protocol (Houshmand et
al., 2017). Briefly, samples were washed using PBS, CFSE
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was added to the cell suspension as a cell division tracking
reagent, and the mixture was incubated at 37 °C for 20 min.
Subsequently, FBS was utilized in order to negate any extra
CFSE in the solution. The cells were then centrifuged, the
supernatant was removed, and the cells were added to each
well of a 24-well plate.
2.8. Cell cycle analysis
To determine the effect of PVT1 knock-down in regulating
the cell cycle and verify the results of the CFSE assay, a cell
cycle analysis was performed. Briefly, samples were washed
and resuspended in Tris buffer. Afterward, an RNAseand DNA-specific fluorochrome solution, composed
of propidium iodide in 0.1% sodium citrate, plus 0.1%
Triton X-100, was added to the cells. The samples were
then incubated at 37 °C for 15 min and analyzed by flow
cytometry.
2.9. Statistical analysis
Statistical analysis of the results was performed by an
analysis of variance (ANOVA) test using SPSS software
(IBM Corp., USA). Data are presented as mean ± standard
deviation. P < 0.05 was considered significant. All
graphs were designed using GraphPad Prism 7 software
(GraphPad Inc., USA).
3. Results
3.1. Upregulation of PVT1 and c-Myc
The expression levels of lncRNA PVT1 and c-Myc in the
Jurkat cell line were measured before knock-down of the
lncRNA. The results demonstrate higher expression of
PVT1 lncRNA in the ALL cell line than in normal cells.
Meanwhile, the level of c-Myc was considerably higher
compared to the control group (Figure 1), showing that
as far as ALL is concerned, the c-Myc oncogene is most
important. To verify the interaction of these two oncogenes,
PVT1 knock-down was performed. The decrease in PVT1
expression is shown in Figure 2.
3.2. Knock-down of lncRNA PVT1 regulates c-Myc
apoptotic and cell cycle genes
Our results demonstrate that PVT1 has a role in ALL
pathogenesis, in which knock-down of lncRNA leads to
the reduction of c-Myc and Bcl2, and augments caspase-3,
p15, and p16 expression (Figure 3). As the c-Myc
diminished significantly, it affected the development
of cells, which was verified by the proliferation assay.
Meanwhile, our experiment shows that PVT1 knockdown results in apoptosis initiation and changes in the cell
cycle regulator genes; consequently, an apoptosis assay and
cell cycle analysis were performed.
3.3. Downregulation of the c-Myc protein in PVT1
knock-down cells
Flow cytometric detection of intracellular c-Myc revealed
a decrease in the c-Myc-positive cell population within
the siRNA PVT1-treated cells. In parallel, the MFI,
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Figure 1. Relative expression of PVT1 and c-Myc in Jurkat cells.
*: P ˂ 0.05.
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Figure 2. Relative expression of PVT1 in Jurkat cells after
treatment with siRNA PVT1. *: P < 0.05.

which represents the median fluorescent intensity of the
antibody-reacted cells, showed a significant decrease in
siRNA PVT1-treated cells (Figure 4). Subsequently, we
examined the protein expression level of c-Myc using
western blot analysis. The results demonstrated that PVT1
knock-down significantly diminished c-Myc protein
expression in the Jurkat cells.
3.4. PVT1 plays a role in apoptosis
To investigate the role of PVT1 knock-down and its effect
on the fate of cells, an apoptosis assay was performed 48 h
after siRNA treatment. The flow cytometry results verified
the qRT-PCR and showed a marked increase in apoptosis
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Figure 3. Relative expression of c-Myc, apoptotic, and cell cycle
genes in Jurkat cells during siRNA PVT1 treatment. *: P < 0.05.
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Figure 4. Expression of intracellular c-Myc protein within Jurkat cells treated with siRNA PVT1. A) Flow cytometry histograms; RN1
represents the percentage of c-Myc-positive cells. B) The percentage and MFI of positive cells in different groups. *: P < 0.05. C) Western
blot for c-Myc expression in Jurkat cell line following standard protocol. Left band represents pretreatment, middle band shows cells
treated with anti-PVT1-siRNA, and right band shows cells treated with PVT1-siRNA.
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in the Jurkat-transfected cells compared to the control
group (Figure 5).
3.5. PVT1 knock-down affects proliferation
To demonstrate the role of PVT1 in the enhancement
of proliferation via diverse pathways, a CFSE assay
was performed using flow cytometry and fluorescent
microscopy after siRNA treatment. CFSE is a fluorescent
dye that divides equally between cells during cell
division. Therefore, reduction of fluorescent intensity
is associated with the rate of proliferation. Our results
show that fluorescent intensity was remarkably higher
in the PVT1 knock-down cells compared to the control
group. Assessment of CFSE via fluorescent microscopy
confirmed the flow cytometry analysis and showed lower
fluorescent intensity in the control group (Figure 6).
This result indicates the impact of PVT1 knock-down
in the suppression of proliferation and regulation of cell
development.

3.6. Cell cycle regulation via lncRNA PVT1
To confirm the results of the CFSE assay and assert the
role of PVT1 in cell cycle regulation, a cell cycle analysis
was performed. Our findings show that after PVT1 knockdown, there was a significant increase in the G0/G1 phase,
and the S phase population diminished dramatically during
the experiment compared to the control group (Figure 7).
These results, like those of the CFSE assay, demonstrate the
role of PVT1 in cell cycle regulation.
4. Discussion
ALL is a heterogeneous hematologic malignancy,
recognized by impaired cell differentiation and
proliferation processes, which engender the accumulation
of cancerous cells in bone marrow and peripheral blood
(Pui, 2000). Although the potential for achieving complete
remission (CR) in pediatric ALL cases is promising,
because of relapse, CR declines to about 40% in adults,
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Figure 5. Apoptosis assay in Jurkat cells treated with PVT1 siRNA. A) Flow cytometry graphs; Q3 shows the percentage of viable cells,
while proapoptotic, apoptotic, and necrotic populations are represented by Q1, Q2, and Q4, respectively. B) The summarized percentage
of viable cells in different groups. *: P < 0.05.
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Figure 6. Proliferation rate in Jurkat cells treated with PVT1 siRNA by CFSE assay. A) Flow cytometry analysis of TF-1 cells on day 0
and after 48 h of treatment. B) The overall MFI of CFSE in different groups, showing the lower proliferation rate in PVT1 siRNA-treated
cells. C) Fluorescent microscopy pictures of CFSE assay in different groups (20×).
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Figure 7. Cell cycle analysis of Jurkat cells in different conditions. A) RN1, RN2, and RN3 respectively represent G0/G1, G2/M,
and S phases. B) Distribution of cells between cell cycle phases in groups. *: P < 0.05.

which is considered a major hurdle for successful treatment
(Jabbour et al., 2015). The conventional treatment protocol
comprises the use of intensive chemotherapy agents with
associated complications. Thus, emerging new therapies,
such as monoclonal antibodies and molecular therapies,
may promote more effective clinical outcomes (Pui and
Jeha, 2007; Tatar et al., 2016). Different lncRNAs take
part in normal lymphoid cell development, but various
experiments have shed light on some lncRNAs like
LUNAR1 and NALT that, by interacting with NOTCH1,
lend a hand in leukemia development (Wallaert et al.,
2017). In this study, for the first time, we show the interplay
between lncRNA PVT1 and its downstream target in an
ALL cell line and elucidate the role of PVT1 knock-down
in the suppression of leukemic cell development.

The 8q24 chromosomal region, as the location of PVT1
and c-Myc, includes a gene desert region and is a common
site for different genetic aberrations (Huppi et al., 2012).
Various studies demonstrated the coexpression pattern of
these two oncogenes, which may participate in the same
signaling pathways (Riquelme et al., 2014; Colombo et
al., 2015). Our results show that the expression level of
lncRNA PVT1 was significantly higher in the ALL cell
line in comparison to the control group and in accordance
with the results of other studies (Li et al., 2015; Guo et
al., 2017). The expression of lncRNA PVT1 correlated
with c-Myc expression. Meanwhile, after using siRNA
PVT1, not only was the expression level of lncRNA PVT1
and c-Myc mRNA downregulated, but the protein level
of the c-Myc onwcogene was also remarkably reduced.
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The presence of lncRNA PVT1 is an indispensable part
of c-Myc expression, so the upregulation of lncRNA in
various cancers preserves c-Myc phosphorylation and the
subsequent degradation of this oncogene (Hamilton et al.,
2015), which our findings confirmed.
Our experiments emphasize the role of PVT1 in apoptosis
in the ALL cell line, in which the knock-down of lncRNA
is accompanied by cell death. Overexpression of lncRNA
PVT1 in ovarian cancer shows the role of this oncogene
in apoptosis inhibition. In this regard, knock-down of
lncRNA initiates the apoptosis process in colorectal and
ovarian cancers (Takahashi et al., 2014; Liu et al., 2015).
Meanwhile, qRT-PCR confirmed the flow cytometry data
that indicated significant enhancement of caspase-3 and
reduction in Bcl2 expression levels. The mechanism of
apoptosis initiation is attributed to the elevation of TGFβ1
as well as the degradation of the c-Myc protein within the
PVT1 knock-down cells.
Accumulated evidence indicates that lncRNA also
participates in the cell cycle and proliferation regulation
in various cells (Colombo et al., 2015). Different studies
show that knock-down of PVT1 results in G0/G1 phase
arrest, attenuating the progression of the cell cycle and,
in turn, impairing proliferation ability (Zeng et al., 2015;
Chen et al., 2017). The CFSE assay showed that although
fluorescent intensity decreased in all groups in comparison
to day 0, the CFSE dye was highly preserved in the PVT1
knock-down cells in contrast to the control group, which

highlights the role of PVT1 knock-down in proliferation
inhibition. Meanwhile, the cell cycle analysis showed a
reduction in the S and G2/M phases and G0/G1 arrest in
PVT1 knock-down cells, which confirms the results of the
proliferation analysis. As different studies have reported a
link between PVT1 and various molecules, such as p21,
p15, p16, and the NOP2 protein, in cell cycle regulation
(Kong et al., 2015; Cui et al., 2016; Wu et al., 2017), we
measured the expression level of p15 and p16 in the ALL
cell line. Our results show that the mRNA level of tumor
suppressors p15 and p16 considerably increased in siPVT1 treated cells, which along with previous findings
may show a part of a PVT1 target in regulating ALL
cell development. On the other hand, c-Myc apparently
controls cell proliferation and the cell cycle, which in
normal cells are tightly regulated by a different mechanism
and are elevated in almost all malignant conditions (Zörnig
and Evan, 1996; Schmidt, 1999). Other studies show
that inhibition of c-Myc induces apoptosis, lowers the
proliferation rate, and enhances G0/G1 arrest in cancerous
cells (Wang et al., 2008; Jeong et al., 2010).
In conclusion, through its interaction with different
intracellular pathways, PVT1 potentiates tumorigenic
activity and is considered an important RNA in leukemic
cells. Therefore, inhibition of this oncogene would help to
eliminate these malignant cells and provide a useful option
for targeted therapy for leukemia.
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